Phenomic AI, a Toronto, Canada-based biotech using AI/ML to reveal drug targets that emerge from cell-cell interactions and drive novel antibody drug discovery for challenging diseases, launched with US$6m in seed financing.
The round was led by CTI Life Sciences Fund and joined by AV8 Ventures, Luminous Ventures, and Viva BioInnovator. Current investors, Garage Capital, Hike Ventures, and Cantos Ventures, also joined the round.
The proceeds of the financing will support preclinical studies for two validated cancer drug targets discovered with the company’s platform as well as discover and advance additional drug targets into the company’s pipeline.
Led by Sam Cooper, CEO, Phenomic AI a drug discovery company for cancer and fibrosis. The company’s platform incorporates advanced AI/ML tools to enable the screening of complex interactions at-scale in multi-cell systems to discover novel drug targets to be advanced internally or with partners. Phenomic AI also has offices in Boston.
Phenomic AI also announced the appointments of Dr. Michael (Mike) Briskin, as Chief Scientific Officer (CSO), and Nobel Laureate James (Jim) P. Allison, Ph.D. and Padmanee (Pam) Sharma, M.D., Ph.D., to its Scientific Advisory Board (SAB).